文献速递艾滋病与性传播感染病毒性肝炎

HIV感染者换用长效卡博特韦/利匹韦林后的乙肝结局

Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles.
PubMed 文献 · Clin Infect Dis · 2026-01-01

西班牙巴塞罗那医院诊所2023年2月至2025年2月的前瞻性队列纳入741例启动长效卡博特韦/利匹韦林(LA-CAB/RPV)的HIV感染者,评估乙肝血清学背景下的HBV再激活与新发感染风险。基线无慢性乙肝者中未观察到HBV再激活或新发感染;4例未被识别的慢性HBV感染者中2例出现临床再激活,均换回含替诺福韦方案。

要点

  • 基线无慢性乙肝者换用LA-CAB/RPV未见HBV再激活或新发感染。
  • 慢性HBV感染者换用后出现临床再激活,应避免该方案。
  • 换药前需完善HBV筛查、疫苗接种与肝功能随访。

核心结论

  • LA-CAB/RPV在既往HBV暴露者(包括孤立抗-HBc阳性)中似乎安全,但慢性HBV感染者可出现再激活。
  • 全面HBV筛查、疫苗接种和肝脏监测是必需的。

研究设计与样本

  • 前瞻性队列研究,纳入2023年2月至2025年2月在Hospital Clínic Barcelona启动LA-CAB/RPV的HIV感染者,共741例。
  • 基线评估HBV血清学、疫苗接种状态和肝功能;随访第12、28周及此后每6个月常规查肝功能,异常时查HBV血清学/DNA。

主要发现

  • 741例中92%为顺性别男性,中位年龄43岁(IQR 35-52),454例(61%)有疫苗诱导免疫,25%既往HBV暴露(抗-HBc阳性),3%为孤立抗-HBc。
  • 中位随访54周(IQR 28-77);基线无慢性乙肝者中未观察到HBV再激活或新发感染。
  • 4例(0.5%)未被识别的慢性HBV感染者(HBsAg阳性)启动LA-CAB/RPV,其中2例出现临床HBV再激活、2例换药后稳定,4例均换回含替诺福韦方案。
  • 随访中转氨酶升高见于17%的队列,与HBV血清学状态无关。

关键数值与推荐

  • HBV再激活定义:抗-HBc阳性/HBsAg阴性者由HBsAg阴性转为阳性或可检出HBV DNA,或慢性HBV(HBsAg阳性)者HBV DNA升高≥1 log或≥100 IU/mL。
  • HBV新发感染定义:HBV未暴露者出现HBsAg血清学转换。

临床怎么用

  • 启动LA-CAB/RPV前应完成HBV血清学筛查,识别慢性HBV感染者。
  • 慢性HBV感染者不宜使用LA-CAB/RPV,应保留含替诺福韦方案。
  • 对既往HBV暴露者(含孤立抗-HBc)可考虑使用,但需常规随访肝功能。

局限性

  • 单中心前瞻性队列,随访时间有限(中位54周)。
  • 慢性HBV感染者样本量很小(4例),相关结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-acting cabotegravir/rilpivirine (LA-CAB/RPV) therapy for HIV, lacks activity against hepatitis B virus (HBV). We evaluate HBV serological profiles and risk of HBV reactivation (HBVr) or incident infection (HBVi) in people with HIV (PWH) switching to LA-CAB/RPV. METHODS: Prospective cohort study of PWH initiating LA-CAB/RPV at Hospital Clínic Barcelona between February/2023 and February/2025. HBV serology, vaccination status, and liver function tests (LFTs) were assessed at baseline. Follow-up LFTs were performed routinely (weeks 12, 28, and every 6 months), and HBV serology/DNA assessed if abnormal LFTs, acute hepatitis or clinical suspicion of reactivation. HBVr was defined as conversion from HBsAg negative to positive or detectable HBV DNA in anti-HBc-positive/HBsAg-negative individuals, or as HBV DNA ≥1 log increase or ≥100 IU/mL in chronic HBV (HBsAg-positive) participants. HBVi was defined as HBsAg seroconversion in HBV unexposed individuals. RESULTS: Among 741 participants-92% cis-gender male, median age 43 (IQR 35-52)-454 (61%) had vaccine-induced immunity and 25% had prior HBV exposure (anti-HBc-positive), with 3% showing isolated anti-HBc. Median follow-up was 54 weeks (IQR 28-77). No HBVr or HBVi were observed in people without chronic hepatitis at baseline. Four individuals (0.5%) with unnoticed chronic HBV infection (HBsAg-positive) started LA-CAB/RPV; two developed clinical HBVr and two remained stable after regimen switch, all four switched back to tenofovir-containing therapy. Transaminase elevations during follow-up occurred in 17% of the cohort, regardless of HBV serostatus. CONCLUSIONS: LA-CAB/RPV appears safe in individuals with prior HBV exposure, including isolated anti-HBc. Comprehensive HBV screening, vaccination, and liver monitoring are essential.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Foncillas A, Ambrosioni J, Sempere A, et al. Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles. Clin Infect Dis. 2026. PMID: 41539988. doi:10.1093/cid/ciag023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。